Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline Offering Free Access to Potential Malaria Compounds

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK CEO Andrew Witty is making another push for cooperation in malaria drug research, offering access to 13,500 compounds and the chance for 60 scientists to work at its research centre in Spain.

You may also be interested in...



Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies

MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development

GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives

Tres Cantos lab's initial focus is on on malaria, tuberculosis, and kinetoplastid diseases.

GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives

Tres Cantos lab's initial focus is on on malaria, tuberculosis, and kinetoplastid diseases.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel